The novel diazabicyclooctenone ETX2514 is a potent, broad-spectrum serine β-lactamase inhibitor that restores sulbactam activity against resistant The frequency of spontaneous resistance to sulbactam-ETX2514 in clinical isolates was found to be 7.6 × 10 to <9.0 × 10 at 4× MIC and mapped to residues near the active site of penicillin binding protein 3 (PBP3). Purified mutant PBP3 proteins demonstrated reduced affinity for sulbactam. In a sulbactam-sensitive isolate, resistance also mapped to stringent response genes associated with resistance to PBP2 inhibitors, suggesting that in addition to β-lactamase inhibition, ETX2514 may enhance sulbactam activity in via inhibition of PBP2.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786785PMC
http://dx.doi.org/10.1128/AAC.01576-17DOI Listing

Publication Analysis

Top Keywords

spontaneous resistance
8
β-lactamase inhibitor
8
clinical isolates
8
frequency mechanism
4
mechanism spontaneous
4
resistance sulbactam
4
sulbactam combined
4
combined novel
4
novel β-lactamase
4
inhibitor etx2514
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!